UK government secures groundbreaking COVID-19 antivirals.
Although we welcome further partnership between the government and pharmaceutical industry in the provision of effective agents to manage the COVID-19 pandemic, we urge caution with the widescale use of ritonavir, given its propensity for causing clinically significant drug–drug interactions with commonly prescribed and over-the-counter medications.
PF-07321332 is a SARS-CoV-2 protease inhibitor currently being assessed in phase 3 trials for its safety and efficacy in the treatment of non-hospitalised adult patients with COVID-19 who are not at increased risk of developing severe illness. The drug is also being explored as a post-exposure prophylaxis agent in patients found to have been exposed to SARS-CoV-2. Treatment duration is 5–10 days, and PF-07321332 is co-administered with low-dose ritonavir to boost and maintain plasma concentrations of the novel agent.
This strategy has reduced the frequency of dosing in HIV antiretroviral therapy, pill burden, impact of food on bioavailability, and variability of systemic drug exposure, and has improved treatment efficacy.
- Renjifo B
- van Wyk J
- Salem AH
- Bow D
- Ng J
- Norton M
- Foisy M
- Yakiwchuk E
- Hughes C
Other drug transporters inhibited by ritonavir include the breast cancer resistance protein (ABCG2), the organic anion transporting polypeptides (hOCT1) in the liver, and MATE1, which is important in renal drug handling.
- Kis O
- Robillard K
- Chan GN
- Bendayan R
Although ritonavir has been expertly managed in the context of combined HIV antiretroviral therapy, the potent boosting and induction effects of the drug have led to various interaction issues with co-medications, encompassing prescribed, over-the-counter, and recreational agents. Concomitant use of ritonavir with some drugs is absolutely contraindicated because of the risk of clinically significant interactions that might lead to life-threatening adverse events. Such agents include statins, steroids, sedative hypnotics, anticoagulants, and antiarrhythmic therapies, many of which are prescribed separately in older populations (aged ≥70 years) at the greatest risk of complications from SARS-CoV-2 infection.
- Waters L
- Ahmed N
- Angus B
- et al.
and by liaising closely with colleagues experienced in the treatment of HIV infection, to reduce the potential for clinically significant iatrogenic adverse or life-threatening events
JH has received funding in the form of a research fellowship from the CW+ charity and The Westminster Medical School Research Trust; and has received honoraria from Gilead, unrelated to this Correspondence. SJCP has received a research grant from the Scientific Exploration Society–Viscount Gough, unrelated to this Correspondence. NM has received speaker fees from Beyer and Pfizer; and received educational support from Eumedica and Baxter. GWD has received consultation fees from DNA Nudge. LSPM has consulted for and received speaker fees from bioMerieux, Pfizer, Eumedica, Shionogi, Pulmocide, Umovis Labs, DNA Electronics, Profile Pharma, and Dairy Crest; and received research grants from the UK National Institute for Health Research (NIHR), LifeArc, and the CW+ charity. RJ has received honoraria, speaker fees, travel support, or research grant funding from Gilead, ViiV Healthcare, Bristol Myers Squibb, Abbvie, Janssen, and Merck. All other authors declare no competing interests. JH acknowledges support from the CW+ charity and The Westminster Medical School Research Trust. LSPM acknowledges support from the NIHR, Imperial Biomedical Research Centre, and the NIHR Health Protection Research Unit in health-care associated infection and antimicrobial resistance at Imperial College London, in partnership with Public Health England. The views expressed in this Correspondence are those of the authors, and not necessarily those of the National Health Service, the NIHR, or the UK Department of Health.
References
- 1.
UK government secures groundbreaking COVID-19 antivirals.
- 2.
Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
J Antimicrob Chemother. 2004; 53: 4-9
- 3.
Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.
AIDS Rev. 2015; 17: 37-46
- 4.
Induction effects of ritonavir: implications for drug interactions.
Ann Pharmacother. 2008; 42: 1048-1059
- 5.
The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.
Trends Pharmacol Sci. 2010; 31: 22-35
- 6.
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update).
Article Info
Publication History
Published: 01 January 2022
Identification
DOI: https://doi.org/10.1016/S0140-6736(21)02657-X
Copyright
© 2021 Elsevier Ltd. All rights reserved.
ScienceDirect
Access this article on ScienceDirect